Welcome to our dedicated page for Journey Medical news (Ticker: DERM), a resource for investors and traders seeking the latest updates and insights on Journey Medical stock.
Journey Medical Corporation (Nasdaq: DERM) is a commercial-stage pharmaceutical company that focuses on selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions. The company reports that it currently markets eight branded FDA-approved prescription drugs that help treat and heal common skin conditions, and it is based in Scottsdale, Arizona.
The news flow around Journey Medical often centers on its dermatology portfolio and, in particular, Emrosi (DFD-29), an FDA-approved low-dose oral minocycline formulation indicated for the treatment of inflammatory lesions (papules and pustules) of rosacea in adults. Company press releases highlight clinical trial milestones, such as pooled Phase 3 efficacy analyses demonstrating statistical superiority of DFD-29 versus placebo and an active comparator, as well as Phase 1 data published in the Journal of Drugs in Dermatology showing no detectable impact on skin, gastrointestinal or vaginal microbiota over 16 weeks in healthy adults.
Investors following DERM news can also expect updates on quarterly financial results, revenue trends, and the commercial performance of Emrosi and other branded dermatology products. Journey Medical regularly issues releases on its net product revenues, gross margin metrics, and developments such as expanded payer access for Emrosi and inclusion in the Russell 2000 and Russell 3000 indices. Additional news items may cover corporate events, investor conference participation, credit agreement amendments, and capital markets activities disclosed through SEC filings and press announcements.
This news page aggregates Journey Medical’s press releases and related coverage so readers can review developments in its dermatology product portfolio, clinical data presentations, and public company updates in one place.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.